XML 58 R27.htm IDEA: XBRL DOCUMENT v3.25.3

Segment Disclosures (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Significant Expense

The table below summarizes the significant expense categories regularly reviewed by the CODM for the three and nine months ended September 30:

			Three Months Ended September 30,
			2025						2024
Operating expenses:
Clinical product candidates			$	15,285					17,338
Pre-clinical product candidates			480						359
Employee costs- research and development			2,463						2,074
Employee costs-general and administrative			1,661						1,575
Non-cash stock compensation			3,614						1,910
Depreciation expense			40						42
Professional fees and other segment expenses			2,450						2,428
Total operating expenses			25,993						25,726
Loss from operations			(25,993)						(25,726)
Interest income			419						776
Other income (expense)			(5)						582
Net loss			$	(25,579)					$	(24,368)
			Nine Months Ended September 30,
			2025						2024
Operating expenses:
Clinical product candidates			$	50,776					47,220
Pre-clinical product candidates			825						760
Employee costs- research and development			7,224						5,955
Employee costs-general and administrative			5,305						4,279
Non-cash stock compensation			7,555						6,541
Depreciation expense			126						99
Professional fees and other segment expenses			8,090						7,567
Total operating expenses			79,901						72,421
Loss from operations			(79,901)						(72,421)
Interest income			843						2,961
Change in fair value of the tranche rights			—						(4,796)
Other income (expense)			1,186						(1,076)
Net loss			$	(77,872)					$	(75,332)

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration